Drugs / BBV121
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04478656 | Jun → Nov 2017 | Zika virus infectious disease | Bharat Biotech International Limited | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBV121 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04478656 ↗ |
| Modality | Vaccine | “purified inactivated adsorbed Zika virus vaccine” NCT04478656 ↗ |
| Route | Intramuscular | “The investigational product is administered intramuscularly on Day 0 and 28” NCT04478656 ↗ |